http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006052496-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5bfbc9b8f8d57d4847dae1fa336a843 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_84f2cdf75b52cf1e1da855fe63352799 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_40a8ca3254d9c245a4b63f7eb7403809 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2801161432ce71d3a00f232083121490 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9879d3b2d65050f3cfc821802d8dd624 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-426 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-175 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 |
| filingDate | 2005-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba2631ca712bacc3325ff1fa22c92619 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7f399f9c09d59f59630accb9c1eb043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9306cc028308458ee41a0897a9beffa8 |
| publicationDate | 2006-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2006052496-A2 |
| titleOfInvention | Compound useful for the treatment or prevention of cognitive disorders associated with diabetes and the use thereof |
| abstract | Described is the efficient synthesis of an easy to manipulate and utilize, soluble tartrate salt of a potent, reversible butyrylcholinesterase inhibitor, (-)-(3aS)-3a-methyl -1,2,3,3a,8,8a-hexahydropyrrolo-[2,3-b]indol-5-yl N-4'-isopropylphenylcarbamate ('MHI tartrate'), for use in altering the enzymatic activity of butyrylcholinesterase and/or acetylcholinesterase in a subject exhibiting or predicted to exhibit cognitive disorders associated with diabetes. Subjects may be suffering from or predicted to suffer from abnormal acetylcholinesterase and/or butyrylcholinesterase activity levels or from an inability to metabolize or catabolize blood sugar normally. The method comprises administering to the subject an effective amount of MHI tartrate dispensable in discrete pharmaceutically useful dosages. MHI tartrate effectively inhibits both acetylcholinesterase and butyrylcholinesterases and additionally is highly selective for butyrylcholinesterase over acetylcholinesterase. |
| priorityDate | 2004-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 233.